HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can You Kick It? Yes You Can, With Six New Foot-Care Products In The UK

Executive Summary

New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.

Galderma Re-Launches Curanail After GSL Switch

Reclassified from pharmacy status last year by the UK's Medicines and Healthcare products Regulatory Agency, Galderma SA has now launched its Curanail W/V 5% Medicated Nail Lacquer (amorolfine) anti-fungal treatment as a general sales list medicine in the UK.

Originally marketed under the Loceryl brand and authorized as a prescription-only medicine in 1991, Curanail was switched to OTC status in 2006.

According to the MHRA, Curanail is licensed as an OTC medicine in roughly 34 countries worldwide, with 25 of these in Europe.

Assessing the safety of the product as part of Galderma’s GSL switch application last year, the MHRA said that amorolfine had a “good safety profile with very few side effects reported in clinical studies, or when the product was marketed as a prescription-only or pharmacy-only medicine.”

Furthermore, in the form of a nail lacquer, the MHRA added, there was “very little absorption of amorolfine into the blood system to be any cause for concern.”

Galderma has re-launched Curanail – which has an recommended retail price (RRP) of £29.99 ($37.99) – with a new TV-spot, featuring a woman who is shy because she has a fungal nail infection.

 

 

Galderma's TV Spot for Curanail in the UK
Open Media

RB Adds Verruca Pen To Scholl Range

“Click, apply, leave to dry” are Reckitt Benckiser Healthcare’s instructions for the new Verruca & Wart Complete Treatment Pen addition to its Scholl foot-care range in the UK.

In a YouTube video for the product – which features an “easy, one-click precision applicator” and is suitable for adults and children above four years of age – RB explains how its new verruca pen can be used to achieve “visible results in one week.”

 

 

RB's Instructional Video For ITS Scholl Verruca Pen

Open Media

Available to buy now for an RRP of £14.99 ($19.08), the pen used trichloroacetic acid to “cause the thickened skin of the verruca to peel, removing the virus and allowing healthy skin to appear,” RB explained. 

Vemedia Competes With Excilor

RB's Verruca pen faces competition in the UK from Dutch consumer healthcare firm Vemedia Group, which has introduced a new two-in-one treatment for verrucae and warts under its established Excilor brand.

“Warts and verrucas are ugly, un-hygienic and can be painful,” Vemedia noted. “Excilor 2in1 Wart & Verruca Treatment offers an effective treatment for warts and verrucae in a much shorter treatment duration.”

Excilor 2in1 Wart & Verruca Treatment used Vemedia’s trademarked “DuoActive Technology,” the firm explained, which combined freeze and gel treatments in one device.

“By targeting the wart and verruca simultaneously,” Vemedia pointed out, “DuoActive technology delivers higher cure rates than most other products on the market today, in a shorter treatment duration of just five days.”

 

Excilor

Vemedia's New  Excilor 2in1 Wart & Verruca Treatment  

At a higher price point than RB’s pen-based verruca treatment at £24.99 per pack, Excilor 2in1 Wart & Verruca Treatment is available now nationwide in pharmacies.

Getting Off On The Right Foot: Blistex, Epitact and Dermatonics

Turning to non-medicinal launches, Blistex Inc. has extended its Odor-Eaters line of foot-care products in the UK with new Fatigue-Reducing Odor-Destroying Insoles.

The “first insole that combines real shock-absorbing support with serious odor-controlling technology,” Blistex said that the product used Odor-Eaters’ “proven technology” to protect feet from odor and control wetness.

Meanwhile, France-based manufacturer Millet Innovation SA has launched in the UK a new foot-care product that limits pressure and rubbing caused by bunions (hallux valgus).

Marketed under its Epitact brand, Millet said its Hallux Valgus Protector – which contains a 1mm-thick disc with the firm’s patented Epithelium 26 gel to soothe discomfort caused by bunions – was “easy to position,” could be machine washed and was suitable for either the left or right foot.

Finally, natural skin-care manufacturer Dermatonics has announced its Natural Care Heel Balm, Soothing Foot Cream and Ultra-Cool Foot Gel products – which contain manuka honey, colloidal oatmeal and chestnut, arnica and peppermint respectively – are now available to buy in “larger Boots stores” in the UK.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel